Search

The last 2 decades have witnessed a dramatic increase in the use of patent citation data in social science research. Facilitated by digitization of the patent data and increasing computing power, a community of practice has grown up that has developed methods for using these data to: measure attributes of innovations such as impact and originality; to trace flows of knowledge across individuals, institutions and regions; and to map innovation networks. The objective of this article is threefold. First, it takes stock of these main uses. Second, it discusses 4 pitfalls associated with patent citation data, related to office, time and technology, examiner, and strategic effects. Third, it highlights gaps in our understanding and offers directions for future research. [ABSTRACT FROM AUTHOR]

Previous studies have questioned the external validity of randomized controlled trial results of acute coronary syndrome (ACS) because of potential selection bias toward healthier patients. We sought to evaluate differences in clinical characteristics and management of patients admitted with non–ST-elevation ACS according to participation in clinical trials over the previous decade. The Canadian ACS I (1999 to 2001), ACS II (2002-2003), GRACE (2004-2007), and CANRACE (2008) were prospective, multicenter registries of patients admitted to hospitals with ACS. We examined 13,556 patients with non–ST-elevation ACS, of whom 1,126 (8.3%) participated in clinical trials. Data were collected on baseline characteristics, medication use at admission and discharge, in-hospital procedures, and in-hospital adverse events. Patients enrolled in clinical trials were younger, more likely to be men, and had fewer co-morbidities. They were significantly more likely to be on several guideline-recommended medications and were significantly more likely to undergo invasive procedures, including coronary angiography, percutaneous coronary intervention, and coronary bypass surgery (all p values <0.001). Unadjusted in-hospital (2.1% vs 0.7%, p = 0.001) and 1-year (8.9% vs 6.3%, p = 0.037) mortality rates were higher in non-enrolled patients. In multivariable analysis, patients who were older, women, had a history of heart failure, and increased creatinine levels on presentation were less likely to be enrolled into clinical trials. In conclusion, significant differences persist in baseline characteristics, treatment, and outcomes between patients enrolled and those not enrolled in clinical trials. Consequently, generalization of ACS clinical trials over the previous decade to the “real-world” patient may remain in question. [Copyright &y& Elsevier]

Abstract: Market failures associated with environmental pollution interact with market failures associated with the innovation and diffusion of new technologies. These combined market failures provide a strong rationale for a portfolio of public policies that foster emissions reduction as well as the development and adoption of environmentally beneficial technology. Both theory and empirical evidence suggest that the rate and direction of technological advance is influenced by market and regulatory incentives, and can be cost-effectively harnessed through the use of economic-incentive based policy. In the presence of weak or nonexistent environmental policies, investments in the development and diffusion of new environmentally beneficial technologies are very likely to be less than would be socially desirable. Positive knowledge and adoption spillovers and information problems can further weaken innovation incentives. While environmental technology policy is fraught with difficulties, a long-term view suggests a strategy of experimenting with policy approaches and systematically evaluating their success. [Copyright &y& Elsevier]

Develops a model of the flow of knowledge process generating subsequent citations to patents as a lens for viewing knowledge diffusion. Data base on the all United States patents granted since 1963; Flexible descriptive model of random processes underlying the generation of citations; Time effects; Technological fields; Institutional type.

Reviews the trends on research and development (R&D) spending in the United States. Overall R&D spending; Basic, academic and federal laboratory research; International comparisons.

Discusses the role of technologies in solving environmental and natural resources problems. Various policy instruments that may be effective in accelerating the diffusion of existing technologies; Examination of the factors that determine the rate of diffusion; Focusing on the potential market failures.